Market Overview

Oppenheimer Downgrades Marinus Pharmaceuticals, Removes Price Target On Disappointing Epilepsy Study Results

Share:
Oppenheimer Downgrades Marinus Pharmaceuticals, Removes Price Target On Disappointing Epilepsy Study Results
Related MRNS
75 Biggest Movers From Yesterday
65 Stocks Moving In Thursday's Mid-Day Session

Oppenheimer has downgraded Marinus Pharmaceuticals Inc (NASDAQ: MRNS) to Perform after the company's first Phase 3 epilepsy study for adult focal onset seizures failed to meet its primary endpoint.

Even though company indicated there were certain sub-demographics of better responders in the greater studied populations, it effectively shut the door on any possibility of moving ganaxolone ahead in adult epilepsy.

Marinus will now focus on ganaxolone for indications within Status Epilepticus and pediatric orphan.

Related Link: In Wake Of Orlando Shooting, Here Are Some Positive Business Responses

"As we only took into account the adult epilepsy indication in our valuation, and left any contribution from the other programs as upside, we are moving to a Perform rating," analyst Rohit Vanjani wrote in a note.

Vanjani said his 2016/2017 EPS estimates move to ($1.55)/($1.10) from prior ($1.57)/($1.22). The analyst also removed his $17 price target.

At the time of writing, shares of Marinus Pharma plunged more than 11 percent to $1.44. The stock touched a new 52-week low of $1.43.

Latest Ratings for MRNS

DateFirmActionFromTo
Jul 2018Cantor FitzgeraldInitiates Coverage OnOverweight
Jun 2018Ladenburg ThalmannInitiates Coverage OnBuy
May 2018BairdInitiates Coverage OnOutperform

View More Analyst Ratings for MRNS
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Downgrades Health Care Price Target Analyst Ratings Tech Trading Ideas

 

Related Articles (MRNS)

View Comments and Join the Discussion!

Manufacturing Workers Face Financial Difficulties

American Airlines Back At October 2014 Levels